Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80
Disc Medicine, Inc.
Disc Medicine, Inc. IRON | 0.00 |
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:
IRON) with a Overweight and raises the price target from $75 to $80.